Monotherapy with α-Blocker or Phosphodiesterase 5 Inhibitor for Lower Urinary Tract Symptoms?

被引：2
|
作者：
Chapple, Christopher R. [1 ]
机构：
[1] Sheffield Teaching Hosp NHS Trust, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England
来源：
EUROPEAN UROLOGY | 2012年 / 61卷 / 05期
关键词：
BENIGN PROSTATIC HYPERPLASIA; ERECTILE DYSFUNCTION; TADALAFIL; SECONDARY; COMBINATION; MANAGEMENT; SILDENAFIL; ALFUZOSIN; SUPERIOR; EFFICACY;
D O I：
10.1016/j.eururo.2012.02.040
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：926 / 927
页数：2
相关论文
共 50 条
  • [21] Phosphodiesterase type 5 inhibitors: a viable treatment option for lower urinary tract symptoms?
    Hatzimouratidis, Konstantinos
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (03) : 245 - 254
  • [22] A Review of Combined Phosphodiesterase-5-Inhibitors and α-Blockers versus Phosphodiesterase-5-Inhibitors Alone for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
    Jackson, Elizabeth M.
    Khooblall, Prajit
    Lundy, Scott D.
    Bajic, Petar
    ARAB JOURNAL OF UROLOGY, 2024, 22 (01) : 13 - 23
  • [23] Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
    Gacci, Mauro
    Andersson, Karl-Erik
    Chapple, Christopher
    Maggi, Mario
    Mirone, Vincenzo
    Oelke, Matthias
    Porst, Hartmut
    Roehrborn, Claus
    Stief, Christian
    Giuliano, Francois
    EUROPEAN UROLOGY, 2016, 70 (01) : 124 - 133
  • [24] Efficacy and tolerability of combination therapy with alpha-blockers and phosphodiesterase-5 inhibitors compared with monotherapy for lower urinary tract symptoms Protocol for a systematic review and network meta-analysis
    Liu Qiangzhao
    Zhang Xiaofeng
    Zhou Fenghai
    Lian Qiong
    Zhang Fa
    Guo Bohong
    Xi Xinsheng
    MEDICINE, 2020, 99 (43) : E22834
  • [25] Factors affecting the efficacy and safety of phosphodiesterase 5 inhibitor and placebo in treatment for lower urinary tract symptoms: meta-analysis and meta-regression
    Sun, Hwa Yeon
    Lee, Bora
    Kim, Jae Heon
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2018, 50 (01) : 35 - 47
  • [26] A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with α-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
    Gacci, Mauro
    Corona, Giovanni
    Salvi, Matteo
    Vignozzi, Linda
    McVary, Kevin T.
    Kaplan, Steven A.
    Roehrborn, Claus G.
    Serni, Sergio
    Mirone, Vincenzo
    Carini, Marco
    Maggi, Mario
    EUROPEAN UROLOGY, 2012, 61 (05) : 994 - 1003
  • [27] Erectile Dysfunction and Lower Urinary Tract Symptoms
    De Nunzio, Cosimo
    Lombardo, Riccardo
    Tema, Giorgia
    Tubaro, Andrea
    CURRENT UROLOGY REPORTS, 2018, 19 (08)
  • [28] Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms
    Shkolyar, Eugene
    Li, Shufeng
    Tang, Jean
    Eisenberg, Michael L.
    JOURNAL OF SEXUAL MEDICINE, 2018, 15 (07) : 982 - 989
  • [29] The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms and the Role of Phosphodiesterase Type 5 Inhibitors
    Koehler, Tobias S.
    McVary, Kevin T.
    EUROPEAN UROLOGY, 2009, 55 (01) : 38 - 48
  • [30] Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms
    H Pimentel
    M Wald
    C Niederberger
    International Journal of Impotence Research, 2008, 20 : 145 - 149
12345